CNS disease in younger patients with aggressive B-cell lymphoma: An analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1267-1273

  Schmitz, N ^a   Zeynalova, S ^b   Glass, B ^a   Kaiser, U ^c   Cavallin Stahl, E ^d   Wolf, M ^e   Haenel, M ^f   Loeffler, M ^b   Truemper, L ^g   Pfreundschuh, M ^h  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c St Bernward Hospital   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f KLINIKUM CHEMNITZ   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

Author keywords

Aggressive lymphoma; Central nervous system relapse; DLBCL; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; GERMANY; HUMANS; INTERNATIONAL COOPERATION; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MEDICAL ONCOLOGY; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDNISOLONE; PREDNISONE; SOCIETIES, MEDICAL; VINCRISTINE; YOUNG ADULT;

EID: 84860448201     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr440     Document Type: Article

References (26)

1. Bjorkholm M, Hagberg H, Holte H et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007; 18(6): 1085-1089.
2. Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18(1): 149-157.
3. Bernstein SH, Unger JM, LeBlanc M et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group. J Clin Oncol 2009; 27(1): 114-119.
4. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15(1): 129-133.
5. Villa D, Connors JM, Shenkier TN et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21(5): 1046-1052.
6. Boehme V, Schmitz N, Zeynalova S et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113(17): 3896-3902.
7. Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105(2): 496-502.
8. Quijano S, Lopez A, Manuel Sancho J et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009; 27(9): 1462-1469.
9. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000; 11(6): 685-690.
10. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102(13): 4284-4289.
11. Pfreundschuh M, Trümper L, Ísterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-391.
12. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104(3): 626-633.
13. Trümper L, Zwick C, Ziepert M et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol 2008; 19(3): 538-544.
14. Pfreundschuh M, Zwick C, Zeynalova S et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008; 19(3): 545-552.
15. Glass B, Kloess M, Bentz M et al. for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006; 107(8): 3058-3064.
16. Glass B, Ziepert M, Reiser M et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of highrisk diffuse large B-cell lymphoma. Ann Oncol 2010; 21(11): 2255-2261.
17. Schmitz N, Nickelsen M, Ziepert M et al. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). ASCO Meeting Abstracts 2011; 29 (15 Suppl): 8002.
18. Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. Response: intrathecal methotrexate and central nervous system events. Blood 2009; 114(9): 1999-2000.
19. Collet D. Modelling Survival Data in Medical Research. Boca Raton, FL: Chapman & Hall/CRC 1999; 80-81.
20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329(14): 987-994. Massachusetts Medical Society.
21. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89(5): 577-583. Springer Japan.
22. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101(2): 466-468.
23. Chamberlain MC. Natural history of CNS relapse in aggressive non-Hodgkin's lymphoma: what have we learned? J Clin Oncol 2009; 27(21): e26.
24. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood 2009; 113(1): 7-10.
25. Pals ST, de Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007; 110(9): 3102-3111.
26. Dietrich PY. Intrathecal MTX for DLBCL: from an inappropriate prophylactic tradition to a medical error? Blood 2009; 114(9): 1999.